165 related articles for article (PubMed ID: 1589447)
1. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
[TBL] [Abstract][Full Text] [Related]
2. Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation.
Pallapies D; Peskar BA
Thromb Res; 1993 Aug; 71(3):217-25. PubMed ID: 8211888
[TBL] [Abstract][Full Text] [Related]
3. Interaction between prostaglandin E1 and nitric oxide (NO).
Katzenschlager R; Weiss K; Rogatti W; Stelzeneder M; Sinzinger H
Thromb Res; 1991 May; 62(4):299-304. PubMed ID: 1866712
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E1 at clinically relevant concentrations inhibits aggregation of platelets under synergic interaction with endothelial cells.
Koga T; Az-ma T; Yuge O
Acta Anaesthesiol Scand; 2002 Sep; 46(8):987-93. PubMed ID: 12190800
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
6. Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.
Sinzinger H; Neumann I; O'Grady J; Rogatti W; Peskar BA
Prostaglandins Other Lipid Mediat; 1998 Apr; 55(5-6):265-75. PubMed ID: 9653766
[TBL] [Abstract][Full Text] [Related]
7. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
Miller OV; Aiken JW; Shebuski RJ; Gorman RR
Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
[TBL] [Abstract][Full Text] [Related]
8. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
10. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
Berry CN; Hoult JR
Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
[TBL] [Abstract][Full Text] [Related]
11. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
Kikura M; Kazama T; Ikeda T; Sato S
Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
[TBL] [Abstract][Full Text] [Related]
12. Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandin endoperoxide PGG2.
Miller OV; Gorman RR
J Cyclic Nucleotide Res; 1976; 2(2):79-87. PubMed ID: 177467
[TBL] [Abstract][Full Text] [Related]
13. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
Bowen R; Haslam RJ
J Cardiovasc Pharmacol; 1991 Mar; 17(3):424-33. PubMed ID: 1711604
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
15. The effects of TFC-612, a 7-THIA prostaglandin E1 derivative, on platelet function.
Motoyama Y; Sakata Y; Seki J; Asada T; Namikawa Y; Horiai H; Ono T
Thromb Res; 1991 Jun; 62(5):471-80. PubMed ID: 1654599
[TBL] [Abstract][Full Text] [Related]
16. The effects of TFC-612, a 7-thia prostaglandin E1 derivative, on platelet function.
Motoyama Y; Sakata Y; Seki J; Asada T; Namikawa Y; Horiai H; Ono T
Thromb Res; 1991 Jul; 63(1):29-38. PubMed ID: 1658963
[TBL] [Abstract][Full Text] [Related]
17. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
[TBL] [Abstract][Full Text] [Related]
18. The binding of 6-oxo-prostaglandin E1 to platelet prostanoid receptors.
Jaschonek K; Renn W; Weisenberger H
Prostaglandins Leukot Med; 1986 Sep; 24(1):79-86. PubMed ID: 3020591
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
20. Developmental Differences in Platelet Inhibition Response to Prostaglandin E1.
Palma-Barqueros V; Torregrosa JM; Caparrós-Pérez E; Mota-Pérez N; Bohdan N; Llanos MDC; Begonja AJ; Sola-Visner M; Vicente V; Teruel-Montoya R; Rivera J; Ferrer-Marín F
Neonatology; 2020; 117(1):15-23. PubMed ID: 31786577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
